Suppr超能文献

用于人类葡萄糖转运蛋白的配体筛选系统作为药物发现的工具

Ligand Screening Systems for Human Glucose Transporters as Tools in Drug Discovery.

作者信息

Schmidl Sina, Iancu Cristina V, Choe Jun-Yong, Oreb Mislav

机构信息

Institute of Molecular Biosciences, Goethe University Frankfurt, Frankfurt am Main, Germany.

Department of Biochemistry and Molecular Biology, Rosalind Franklin University of Medicine and Science, North Chicago, IL, United States.

出版信息

Front Chem. 2018 May 25;6:183. doi: 10.3389/fchem.2018.00183. eCollection 2018.

Abstract

Hexoses are the major source of energy and carbon skeletons for biosynthetic processes in all kingdoms of life. Their cellular uptake is mediated by specialized transporters, including glucose transporters (GLUT, SLC2 gene family). Malfunction or altered expression pattern of GLUTs in humans is associated with several widespread diseases including cancer, diabetes and severe metabolic disorders. Their high relevance in the medical area makes these transporters valuable drug targets and potential biomarkers. Nevertheless, the lack of a suitable high-throughput screening system has impeded the determination of compounds that would enable specific manipulation of GLUTs so far. Availability of structural data on several GLUTs enabled ligand screening, though limited by the fact that only two major conformations of the transporters can be tested. Recently, convenient high-throughput microbial and cell-free screening systems have been developed. These remarkable achievements set the foundation for further and detailed elucidation of the molecular mechanisms of glucose transport and will also lead to great progress in the discovery of GLUT effectors as therapeutic agents. In this mini-review, we focus on recent efforts to identify potential GLUT-targeting drugs, based on a combination of structural biology and different assay systems.

摘要

己糖是所有生命王国生物合成过程中能量和碳骨架的主要来源。它们的细胞摄取由专门的转运蛋白介导,包括葡萄糖转运蛋白(GLUT,SLC2基因家族)。人类中GLUT的功能障碍或表达模式改变与包括癌症、糖尿病和严重代谢紊乱在内的几种常见疾病有关。它们在医学领域的高度相关性使这些转运蛋白成为有价值的药物靶点和潜在的生物标志物。然而,缺乏合适的高通量筛选系统阻碍了迄今能够实现对GLUT进行特异性调控的化合物的确定。尽管由于只能测试转运蛋白的两种主要构象这一事实而受到限制,但几种GLUT的结构数据的可用性使得配体筛选成为可能。最近,已经开发出了方便的高通量微生物和无细胞筛选系统。这些显著的成就为进一步详细阐明葡萄糖转运的分子机制奠定了基础,也将在发现作为治疗剂的GLUT效应物方面取得巨大进展。在本综述中,我们重点介绍基于结构生物学和不同检测系统相结合来鉴定潜在GLUT靶向药物的最新研究成果。

相似文献

6
The SLC2 (GLUT) family of membrane transporters.溶质载体家族 2(GLUT)的膜转运蛋白。
Mol Aspects Med. 2013 Apr-Jun;34(2-3):121-38. doi: 10.1016/j.mam.2012.07.001.

引用本文的文献

本文引用的文献

4
6
SLC Transporters: Structure, Function, and Drug Discovery.溶质载体转运蛋白:结构、功能与药物发现
Medchemcomm. 2016 Jun 1;7(6):1069-1081. doi: 10.1039/C6MD00005C. Epub 2016 Mar 28.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验